Funded Health Care Startups in Stockholm
Among the 20 most recent health care funding entries in Stockholm shown here, Raysearch Laboratories’ $50M round on 2025-03-18 stands out as the only discl…
Among the 20 most recent health care funding entries in Stockholm shown here, Raysearch Laboratories’ $50M round on 2025-03-18 stands out as the only disclosed amount in the $50M+ range, with the next-highest disclosed figure at Neko Health’s $65M on 2023-07-05 (while most other disclosed rounds cluster far below those levels, including ODI Pharma at $380K on 2023-06-01). The disclosed-size spread also has a clear small-end floor: ODI Pharma’s $380K is the smallest disclosed amount, while multiple rounds sit in the single-digit millions (e.g., Corsmed at $4M on 2024-12-18; Medoma at $6M on 2022-09-06).
Dates concentrate across a long tail from 2020-06-01 (Doctrin) to 2025-03-18, but with an especially dense middle window in 2022 and 2023 (e.g., five entries between 2022-01-11 and 2022-09-06; and multiple entries in May 2023 around Series A and early-stage rounds). Stage labeling is mixed: five of 20 rows are “Series Unknown,” and two additional rows are “undisclosed” by amount (Qbtech on 2022-09-01 and Doktor.se on 2022-08-01), limiting comparisons for a subset of deals. All rows list Stockholm (Stockholms Lan) as the location, reinforcing a geographic concentration around the same metro area.
Most recent rounds
20 shownRelated listings
Frequently asked
Which disclosed round is the size outlier in this Stockholm health care set, and how does the rest compare?
Neko Health’s $65M round on 2023-07-05 is the largest disclosed amount in the list; the next-largest disclosed figures include Raysearch Laboratories at $50M on 2025-03-18 and ADDvise at $97M on 2023-05-11. Most other disclosed rounds are far smaller, including several in the $1M–$18M band such as Capitainer ($1M, 2024-02-15) and Health Integrator ($2M, 2021-09-08).
Are there clear time clusters among these 20 recent rounds?
Yes. There is noticeable clustering in 2022–2023, including multiple entries between 2022-01-11 (Cardo Health) and 2022-09-06 (Medoma), and a high-density stretch in May 2023 (e.g., ODI Pharma on 2023-06-01 and Tada Group AB on 2023-05-03, plus ADDvise on 2023-05-11 and Encare on 2023-05-08). The date range spans 2020-06-01 (Doctrin) through 2025-03-18 (Raysearch Laboratories), but activity is most concentrated in that middle window.
What does the stage mix look like, and how much does classification uncertainty affect analysis?
Series A appears multiple times (e.g., Neko Health 2023-07-05, Capitainer 2024-02-15, Cardo Health 2022-01-11, and Health Integrator 2021-09-08). At the same time, five of 20 rows are labeled “Series Unknown” (such as Raysearch Laboratories on 2025-03-18 and ODI Pharma on 2023-06-01), and two rows use “undisclosed” amounts (Qbtech on 2022-09-01; Doktor.se on 2022-08-01), which reduces how confidently stages and amounts can be compared.
How consistently is the geography represented within the table?
Every row lists Stockholm, Stockholms Lan, Sweden as the location, including Raysearch Laboratories (2025-03-18) and Doctrin (2020-06-01). That means the list functions as a single-city slice rather than a multi-metro comparison.
Which entries anchor the smallest disclosed end, and what are the nearby reference points?
ODI Pharma’s $380K on 2023-06-01 is the smallest disclosed amount in the dataset. Nearby low-end disclosed deals include Capitainer at $1M (2024-02-15) and Bemlo at $3M (2022-08-02), contrasting with much larger disclosed rounds like ADDvise’s $97M (2023-05-11) and Neko Health’s $65M (2023-07-05).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.